Results 71 to 80 of about 5,563 (240)
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Journal of Hematology & Oncology, 2021 Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies.
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
doaj +1 more source
OncoImmunology, 2022 Cancer immunotherapy strategies based on the endogenous secretion of T cell-redirecting bispecific antibodies by engineered T lymphocytes (STAb-T) are emerging as alternative or complementary approaches to those based on chimeric antigen receptors (CAR-T)
Ángel Ramírez-Fernández +7 more
doaj +1 more source
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Background Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy.
Sayed Shahabuddin Hoseini +3 more
openaire +3 more sources
American Journal of Hematology, EarlyView.ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Arthritis &Rheumatology, EarlyView.Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Frontiers in ImmunologyBackgroundIn the last decade, chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of hematologic malignancies. However, antitumor responses in solid tumors remain poor, and the difficulty in finding truly tumor-specific ...
Ivana Zagorac +26 more
doaj +1 more source
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
Frontiers in Immunology, 2019 Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells.
Mingpeng Fu +11 more
doaj +1 more source
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
OncoImmunology, 2022 Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials ...
Antonio Tapia-Galisteo +15 more
doaj +1 more source
Antibodies, 2022 Bispecific antibodies (bsAbs) are molecules that simultaneously bind two different antigens (Ags). bsAbs represent a very active field in tumor immunotherapy with more than one hundred molecules currently being tested.
Rita Tavarozzi, Enrica Manzato
doaj +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source